MADRIGAL PHARMACEUTICALS, INC. (MDGL) Stock Profile — Insider Trades & Financials

Revenue$321.1M

Net Income-$58.6M

EPS$-12.85

Market Cap$11.9B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

William Sibold

CEO & Executive Director

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Founded: 2011
Employees: 915
Headquarters: West Conshohocken, Pennsylvania, United States
Website: www.madrigalpharma.com

⚡

Core Efficiency

ROE?

-9.72%

ROA?

-4.65%

D/E Ratio?

1.09

Op. Margin?

-18.57%

📊

Profitability Ratios

Net Margin?

-18.24%

Loading company sections...

MADRIGAL PHARMACEUTICALS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness